Cargando…
Epistatic mutations in PUMA BH3 drive an alternate binding mode to potently and selectively inhibit anti-apoptotic Bfl-1
Overexpression of anti-apoptotic Bcl-2 family proteins contributes to cancer progression and confers resistance to chemotherapy. Small molecules that target Bcl-2 are used in the clinic to treat leukemia, but tight and selective inhibitors are not available for Bcl-2 paralog Bfl-1. Guided by computa...
Autores principales: | Jenson, Justin M, Ryan, Jeremy A, Grant, Robert A, Letai, Anthony, Keating, Amy E |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
eLife Sciences Publications, Ltd
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464773/ https://www.ncbi.nlm.nih.gov/pubmed/28594323 http://dx.doi.org/10.7554/eLife.25541 |
Ejemplares similares
-
The carboxyl-terminal sequence of PUMA binds to both anti-apoptotic proteins and membranes
por: Pemberton, James M, et al.
Publicado: (2023) -
Removal of BFL-1 sensitises some melanoma cells to killing by BH3 mimetic drugs
por: Gangoda, Lahiru, et al.
Publicado: (2022) -
Puma strikes Bax
por: Letai, Anthony
Publicado: (2009) -
A redox switch regulates the structure and function of anti-apoptotic BFL-1
por: Korshavn, Kyle J., et al.
Publicado: (2020) -
Computational design of environmental sensors for the potent opioid fentanyl
por: Bick, Matthew J, et al.
Publicado: (2017)